probenecid has been researched along with Influenza, Human in 6 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Influenza, Human: An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oseltamivir is an inhibitor of influenza virus neuraminidase, which is approved for use for the treatment and prophylaxis of influenza A and B virus infections." | 2.73 | Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ( Cunningham, F; Davey, RT; Deyton, LR; Goetz, MB; Holodniy, M; Lee, KK; Lin, ET; Olivo, N; Penzak, SR; Raisch, DW; Straight, TM, 2008) |
| "Oseltamivir is an ester prodrug of the active metabolite [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a potent and selective inhibitor of neuraminidase enzyme of influenza virus." | 2.70 | The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. ( Barrett, J; Cihlar, T; Hill, G; Ho, ES; Liu, B; Oo, C; Prior, K; Ward, P; Wiltshire, H, 2002) |
| "Antiviral chemotherapeutics that target influenza A virus are available; however, rapid emergence of drug-resistant strains has been reported." | 1.39 | Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. ( Brooks, P; Johnson, S; Perwitasari, O; Tompkins, SM; Tripp, RA; White, C; Yan, X, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holodniy, M | 1 |
| Penzak, SR | 1 |
| Straight, TM | 1 |
| Davey, RT | 1 |
| Lee, KK | 1 |
| Goetz, MB | 1 |
| Raisch, DW | 1 |
| Cunningham, F | 1 |
| Lin, ET | 1 |
| Olivo, N | 1 |
| Deyton, LR | 1 |
| Wattanagoon, Y | 1 |
| Stepniewska, K | 1 |
| Lindegårdh, N | 1 |
| Pukrittayakamee, S | 1 |
| Silachamroon, U | 1 |
| Piyaphanee, W | 1 |
| Singtoroj, T | 1 |
| Hanpithakpong, W | 1 |
| Davies, G | 1 |
| Tarning, J | 1 |
| Pongtavornpinyo, W | 1 |
| Fukuda, C | 1 |
| Singhasivanon, P | 1 |
| Day, NP | 1 |
| White, NJ | 1 |
| Perwitasari, O | 1 |
| Yan, X | 1 |
| Johnson, S | 1 |
| White, C | 1 |
| Brooks, P | 1 |
| Tompkins, SM | 1 |
| Tripp, RA | 1 |
| Butler, D | 1 |
| Howton, JC | 1 |
| Hill, G | 1 |
| Cihlar, T | 1 |
| Oo, C | 1 |
| Ho, ES | 1 |
| Prior, K | 1 |
| Wiltshire, H | 1 |
| Barrett, J | 1 |
| Liu, B | 1 |
| Ward, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01)[NCT00304434] | Phase 4 | 48 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| Phase I, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Oseltamivir in Healthy Obese Thai Adult Subjects[NCT01049763] | Phase 1 | 24 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for probenecid and Influenza, Human
| Article | Year |
|---|---|
Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Topics: Adult; Aged; Antiviral Agents; Chemoprevention; Dose-Response Relationship, Drug; Drug Administratio | 2008 |
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Topics: Acetamides; Adolescent; Adult; Amoxicillin; Animals; Antiviral Agents; Biological Transport; CHO Cel | 2002 |
4 other studies available for probenecid and Influenza, Human
| Article | Year |
|---|---|
Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
Topics: Administration, Oral; Adult; Antiviral Agents; Area Under Curve; Asian People; Biological Availabili | 2009 |
Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.
Topics: Antiviral Agents; Cell Line; Drug Repositioning; Gene Expression; High-Throughput Screening Assays; | 2013 |
Wartime tactic doubles power of scarce bird-flu drug.
Topics: Acetamides; Drug Combinations; Drug Industry; Humans; Influenza, Human; Oseltamivir; Probenecid; Wor | 2005 |
Probenecid with oseltamivir for human influenza A (H5N1) virus infection?
Topics: Acetamides; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Humans; Influenza A Viru | 2006 |